SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Violations of Federal Securities Laws by Certain Officers and Directors of Juno Therapeutics Inc.

NEW YORK--()--Levi & Korsinsky announces it has commenced an investigation of Juno Therapeutics Inc. (“Juno Therapeutics” or the “Company”) (NASDAQ: JUNO) concerning possible violations of federal securities laws.

On June 7, 2016, Juno announced that three patients had died during a clinical trial for the Company’s chemotherapy drug, fludarabine. Following this news, shares of Juno were down more than 31% on intraday trading on July 8, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/juno-therapeutics-juno

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky announces it has commenced an investigation of Juno Therapeutics Inc. concerning possible violations of federal securities laws.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com